We were founded in 2001 as Oryx Pharmaceuticals with the mission of building a Canadian specialty pharmaceuticals company that purchased and licensed innovative pharmaceuticals products for the Canadian marketplace. After a successful history with many notable product approvals, launches and resulting commercial success, the company was acquired by U.S. based Sepracor Inc.
In October 2009, Sepracor Inc. was acquired by Sumitomo Dainippon Pharma Co., Ltd., a top ten stock exchanged-listed pharmaceuticals company based in Osaka, Japan.
The move strengthened Sumitomo Dainippon Pharma's North American based drug development pipeline and commercial capabilities and brought together extensive expertise in two main treatment categories - disorders of the central nervous system (CNS) and respiratory disease.
As part of the continued integration of Sumitomo Dainippon Pharma's North American locations, Sepracor Inc. changed its name to Sunovion Pharmaceuticals Inc in October 2010.